Citigroup raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock from “a Buy” to “a Neutral”. The rating was released on June 26, 2024, according to finviz. The research report ...
Sarepta's future looks a lot more promising now that it's obtained label expansion for Elevidys. And with more therapies and ...
Sarepta Therapeutics (SRPT) closed the last trading session at $143.78, gaining 16.4% over the past four weeks, but there ...
Sarepta Therapeutics SRPT is the market leader in the Duchenne muscular dystrophy (DMD) space. It currently markets four ...
Sarepta Therapeutics SRPT has outperformed the market over the past 10 years by 10.36% on an annualized basis producing an ...
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on ...
Last week the FDA expanded its previous approval for Sarepta Therapeutics’ gene therapy to treat Duchenne muscular dystrophy. Elevidys won accelerated approval from the federal agency last year ...
Uy Ear, an analyst from Mizuho Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
Citigroup raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock from “a Buy” to “a Neutral”. The rating was released on June 26, 2024, according to finviz. The research report ...
On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The ...